Gilead Sciences News

China will provide two imported HIV drugs to patients who develop resistance to cheaper, domestic alternatives, state media said on Monday, going some way to meeting a key demand of AIDS treatment activists.

Pearl Therapeutics Inc., a biopharmaceutical company developing therapeutic products for the treatment of chronic respiratory diseases, today announced the appointment of Howie Rosen to the company's Board of Directors.

MADISON, Wis.-- --BioSystem Development, LLC., a privately held life science analytics company, announces a recently completed investment round that raised just over 1.4 million dollars... LISLE, Illinois-- --SmartSignal Corporation ha annunciato oggi che Gas Natural ha selezionato il software SmartSignal EPI*Center per il monitoraggio di 22 ...

Britain's Health Protection Agency said five cases have been confirmed in Wales of patients infected with H1N1 resistant to oseltamivir -- the generic name of Roche and Gilead Sciences Inc 's antiviral drug Tamiflu.

Gilead Sciences, Inc. and GlaxoSmithKline today announced a licensing agreement to commercialize Viread for the treatment of chronic hepatitis B infection in adults in five countries in Asia.

The purpose of this article is to encourage the American people to read information on drugs they are being prescribed -- especially prescribed to their children -- and to read, read, read ingredients contained on labels -- especially what is being ingested by children.

While the market has staged a nice comeback since the spring and the economy seems to be slowly righting itself, things are still rough out there.

Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks.

H&Q Healthcare Investors appears to a be a decent value now within the closed-end fund universe.

Over his 28 years, Burrill's clients have included Steve Jobs of Apple, Genentech, Amgen and Gilead Sciences.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, biotech giant Gilead Sciences has earned a coveted five-star ranking .

David Gardner called it. Hea TMs up 1,334%! See what Davida TMs recommending that you buy NEXT.

Filed under: Market matters , Abbott Laboratories , Aetna Inc , CIGNA Corp , Gilead Sciences , Stocks to Buy , Cramer on BloggingStocks TheStreet.com's Jim Cramer says the Senate is filled with more-savvy politicians, and the upside for beaten-down names is huge.

FreeBalance , a leading global provider of software solutions for public financial management, is pleased to announce the results of its most recent internal audit which show a dramatic increase in the size and scope of FreeBalance Government Resource Planning software implementations worldwide since 2006.

GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/04/09, Genta Incorporated announced the Company will release its third quarter 2009 financial results on Monday, November 16, 2009.

The drug industry's response to the HIV epidemic is widely viewed as a story of sterling R&D success.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 10/30/09, Gilead Sciences, Inc.

Long-term Studies Show Tenofovir Safety and Efficacy Is Sustained at 3 Years in HBeAg Positive and Negative Hepatitis B Patients SUMMARY: Long-term follow-up data from 2 clinical trials show that tenofovir remained active against hepatitis B virus and was generally well-tolerated for up to 3 years, researchers reported this past weekend at the 60th ...

A bad week for stocks has investors worried. But one top-performing letter remains fully invested.